Open Access<p>Two-Year Outcomes for the Double-Blind, Randomized, Sham-Controlled Study of Targeted Lung Denervation in Patients with Moderate to Severe COPD: AIRFLOW-2</p>
Author(s) -
Arschang Valipour,
Pallav L. Shah,
Felix J.F. Herth,
Christophe Pison,
Christian Schümann,
Ralf-Harto Hübner,
Peter I. Bonta,
Romain Kessler,
Wolfgang Gesierich,
Kaid Darwiche,
Bernd Lamprecht,
Thierry Pérez,
Dirk Skowasch,
Gaëtan Deslée,
Armelle Marceau,
Frank C. Sciurba,
Reinoud Gosens,
Jorine E. Hartman,
Francesca Conway,
Marina Duller,
Martin L. Mayse,
Holly S. Norman,
DirkJan Slebos
Publication year - 2020
Publication title -
international journal of chronic obstructive pulmonary disease/international journal of copd
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.394
H-Index - 67
eISSN - 1178-2005
pISSN - 1176-9106
DOI - 10.2147/copd.s267409
Subject(s) - medicine , copd , exacerbation , randomization , randomized controlled trial , denervation
COPD exacerbations are associated with worsening clinical outcomes and increased healthcare costs, despite use of optimal medical therapy. A novel bronchoscopic therapy, targeted lung denervation (TLD), which disrupts parasympathetic pulmonary innervation of the lung, has been developed to reduce clinical consequences of cholinergic hyperactivity and its impact on COPD exacerbations. The AIRFLOW-2 study assessed the durability of safety and efficacy of TLD additive to optimal drug therapy compared to sham bronchoscopy and optimal drug therapy alone in subjects with moderate-to-severe, symptomatic COPD two years post randomization.